Salignostics develops fast, safe, user-friendly, and cost-effective saliva-based diagnostic solutions. Its cutting-edge technology processes saliva into an analyzable body fluid, offering fast, safe, user-friendly, and cost-effective diagnostic options for self-testing, homecare, point-of-care, and laboratory settings. This addresses the limitations of current diagnostic methods which are expensive, time-consuming, and personnel dependent. Our products facilitate easy saliva self-collection, sample preparation, and rapid detection of a wide array of analytes and biomarkers in a single device. The device can identify human proteins, viral proteins, DNA, and RNA, with the ability to detect a high number of previously unidentifiable biomarkers. This enables non-invasive and painless diagnostics at home. Salignostics holds 4 innovative patents and 2 trade secrets covering its platform technology. The possibility to collect, detect, and test positions us to address a large group of multi-billion-dollar markets, including the home diagnostics market, projected to grow to $10B by 2032. In 2023, we have successfully launched Salistick, the first rapid saliva-based pregnancy test, already available in the UK, Sweden, and Israel. Salignostics plans to reach $70M annual revenues by 2030, through expanding its product reach, developing new saliva-based diagnostic applications, and establishing R&D and commercial collaborations with global diagnostics companies.